B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-69703-7
Affiliations:
3
Authors:
21
Go to article
Institutions Authors Share
Innovent Biologics, Inc., China
21.000000
21.000000
21.000000
 1.00
Interested in Oncology and Carcinogenesis?